Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma

被引:161
作者
Yang, Xiu Hua
Yamagiwa, Satoshi
Ichida, Takafumi [1 ]
Matsuda, Yasunobu
Sugahara, Satoshi
Watanabe, Hisami
Sato, Yoshinobu
Abo, Toru
Horwitz, David A.
Aoyagi, Yutaka
机构
[1] Niigata Univ, Grad Sch Med & Dent Sci, Div Gastroenterol & Hepatol, Niigata, Japan
[2] Juntendo Univ, Sch Med, Div Gastroenterol & Hepatol, Bunkyo Ku, Tokyo 1138421, Japan
[3] Univ Ryukyus, Ctr Mol Biosci, Div Cellular & Mol Immunol, Okinawa, Japan
[4] Niigata Univ, Grad Sch Med & Dent Sci, Div Surg, Niigata, Japan
[5] Niigata Univ, Grad Sch Med & Dent Sci, Div Immunol, Niigata, Japan
[6] Univ So Calif, Keck Sch Med, Dept Internal Med, Div Rheumatol & Immunol, Los Angeles, CA USA
基金
日本学术振兴会;
关键词
regulatory T-cells; tumor immunity; hepatocellular carcinoma; intrahepatic lymphocytes; cytotoxic T lymphocytes;
D O I
10.1016/j.jhep.2006.01.036
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The immune response to tumor-specific antigens is typically unable to control the growth and spread of malignant cells. Accumulating evidence indicates that the suppressive effects of CD4(+) CD25(+) regulatory T-cells are at least partially responsible for the failure of immune-mediated elimination of tumor cells. Methods: We have studied 25 patients with hepatocellular carcinoma (HCC). The liver tissues with HCC were separated into the marginal region of tumor (peri-tumor region) and the non-tumor region distant from the tumor. CD4(+) CD25(+) T-cells were quantified in the blood and the liver by flow cytometry and immunohistochemistry, and their effect on T-cell proliferation and activation was determined. Results: We found a significant increase in both the proportion and absolute numbers of CD4(+) CD25(+) T-cells in the peri-tumor regions, but not in unaffected areas (9.5 4.5 vs. 4.6 2.8%, P = 0.011). C134(+) CD25(+) T-cells isolated from peri-tumor regions displayed phenotype markers characteristic of regulatory T-cells, and expressed Foxp3 mRNA. CD8(+) T-cells in peri-tumor regions were inversely proportional to CD4(+) CD25(+) T-cells in the same region (P < 0.001). Moreover, isolated C134(+) CD25(+) T-cells inhibited autologous C138(+) T-cell proliferation. Conclusions: Our results suggest that CD4(+) CD25(+) T-cells in the marginal region of HCC may play a critical role in controlling CD8(+) cytotoxic T-cell activity and, thereby, contribute to the progression of HCC. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:254 / 262
页数:9
相关论文
共 50 条
  • [31] Effects of montelukast on CD4+ CD25+ regulatory T cell expression in children with acute bronchial asthma
    Chen, Yongxin
    Li, Zengqing
    Tang, Yuanping
    Li, Wenzhong
    Wang, Bo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (02): : 3329 - 3336
  • [32] CD4+CD25+regulatory T-cells role in tumor microenvironment of the squamous cell carcinoma
    Pascalau, Andrei Vasile
    Cheregi, Cornel Dragos
    Muresan, Mihai Stefan
    Sandor, Mircea Ioan
    Huniadi, Carmen Anca
    Nikin, Zoran
    Pusta, Claudia Teodora Judea
    Bodog, Florian Dorel
    Ionescu, Calin
    Pop, Ovidiu Laurean
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2021, 62 (01) : 249 - 253
  • [33] Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
    Roniel Cabrera
    Miguel Ararat
    Yiling Xu
    Todd Brusko
    Clive Wasserfall
    Mark A. Atkinson
    Lung Ji Chang
    Chen Liu
    David R. Nelson
    Cancer Immunology, Immunotherapy, 2013, 62 : 737 - 746
  • [34] Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
    Cabrera, Roniel
    Ararat, Miguel
    Xu, Yiling
    Brusko, Todd
    Wasserfall, Clive
    Atkinson, Mark A.
    Chang, Lung Ji
    Liu, Chen
    Nelson, David R.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (04) : 737 - 746
  • [35] CD4+CD25+ regulatory T cells:: a therapeutic target for liver diseases
    Zheng, Ming-Hua
    Gu, Dian-Na
    Braddock, Martin
    Leishman, Andrew J.
    Jin, Chang
    Wen, Jin-Sheng
    Gong, Yue-Wen
    Chen, Yong-Ping
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (03) : 313 - 326
  • [36] Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma
    Heier, I.
    Hofgaard, P. O.
    Brandtzaeg, P.
    Jahnsen, F. L.
    Karlsson, M.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 152 (02) : 381 - 387
  • [37] Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1:: Increased susceptibility to autoimmune disease
    Nishibori, T
    Tanabe, Y
    Su, L
    David, M
    JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (01) : 25 - 34
  • [38] Decrease of CD4+ CD25+ CD127low FoxP3+ regulatory T cells with impaired suppressive function in untreated ulcerative colitis patients
    Mohammadnia-Afrouzi, Mousa
    Hosseini, Ahmad Zavaran
    Khalili, Ali
    Abediankenari, Saeid
    Hosseini, Vahid
    Maleki, Iradj
    AUTOIMMUNITY, 2015, 48 (08) : 556 - 561
  • [39] Ex-vivo expansion and function identification of CD4+ CD25+ CD127dim regulatory T cells in severe aplastic anemia
    Yan, Li
    Fu, Rong
    Wang, Huaquan
    Liu, Chunyan
    Liu, Hui
    Wang, Ting
    Qi, Weiwei
    Guan, Jing
    Shao, Zonghong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (09): : 8836 - 8846
  • [40] Role of CD25+ CD4+ T cells in acute and persistent coronavirus infection of the central nervous system
    de Aquino, Maria Teresa P.
    Puntambekar, Shweta S.
    Savarin, Carine
    Bergmann, Cornelia C.
    Phares, Timothy W.
    Hinton, David R.
    Stohlman, Stephen A.
    VIROLOGY, 2013, 447 (1-2) : 112 - 120